Guggenheim Decides to Upgrade Wright Medical Group (NASDAQ:WMGI) Stock

June 13, 2018 - By Nellie Frank

Wright Medical Group N.V. (NASDAQ:WMGI) Logo

Wright Medical Group (NASDAQ:WMGI) Stock Upgrade

Guggenheim has upgraded shares of Wright Medical Group (NASDAQ:WMGI) stock to a “Buy” in a research note issued today. WMGI’s past rating was only a “Neutral”.

Wright Medical Group N.V. (NASDAQ:WMGI) Ratings Coverage

Among 6 analysts covering Wright Medical Group (NASDAQ:WMGI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Wright Medical Group has $32.0 highest and $25 lowest target. $27.33’s average target is 6.01% above currents $25.78 stock price. Wright Medical Group had 14 analyst reports since January 2, 2018 according to SRatingsIntel. The company was maintained on Wednesday, February 28 by Robert W. Baird. On Monday, January 22 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, January 8. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, January 17 report. The rating was maintained by Barclays Capital on Wednesday, February 28 with “Overweight”. The stock of Wright Medical Group N.V. (NASDAQ:WMGI) earned “Outperform” rating by BMO Capital Markets on Wednesday, February 28. Piper Jaffray maintained it with “Buy” rating and $28.0 target in Wednesday, February 28 report. The company was maintained on Monday, February 12 by Cantor Fitzgerald. The company was maintained on Monday, April 30 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, March 12.

The stock increased 4.46% or $1.1 during the last trading session, reaching $25.78. About 3.10 million shares traded or 220.94% up from the average. Wright Medical Group N.V. (NASDAQ:WMGI) has declined 9.52% since June 13, 2017 and is downtrending. It has underperformed by 22.09% the S&P500.

Analysts await Wright Medical Group N.V. (NASDAQ:WMGI) to report earnings on August, 1. They expect $-0.07 earnings per share, 0.00 % or $0.00 from last year’s $-0.07 per share. After $-0.01 actual earnings per share reported by Wright Medical Group N.V. for the previous quarter, Wall Street now forecasts 600.00 % negative EPS growth.

Wright Medical Group N.V., a medical device company, designs, makes, markets, and sells extremities and biologics the United States, Europe, the Middle East, Africa, and internationally. The company has market cap of $2.73 billion. The firm offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth. It currently has negative earnings. It also provides sports medicines and other products to mechanically repair tissue-to-tissue or tissue-to-bone injuries.

More notable recent Wright Medical Group N.V. (NASDAQ:WMGI) news were published by: which released: “Wright Medical Announces FDA Premarket Approval for AUGMENT Injectable Bone Graft” on June 13, 2018, also with their article: “CORRECT AND REPLACE: Wright Medical Group NV to Present at Jefferies Global Healthcare Conference” published on May 21, 2018, published: “FDA OKs Wright Medical’s Augment bone graft” on June 13, 2018. More interesting news about Wright Medical Group N.V. (NASDAQ:WMGI) were released by: and their article: “Report: Exploring Fundamental Drivers Behind Syros Pharmaceuticals, J & J Snack Foods, Wright Medical Group NV …” published on May 21, 2018 as well as‘s news article titled: “Wright Medical Group (WMGI) Reports FDA Premarket Approval for AUGMENT Injectable Bone Graft” with publication date: June 13, 2018.

Wright Medical Group N.V. (NASDAQ:WMGI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: